Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

NCT07397338 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

370

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Metastatic Solid Tumors
Non-small Cell Lung Cancer (NSCLC)
NSCLC
Colorectal Cancer (CRC)
CRC

Interventions

DRUG: Daraxonrasib
DRUG: Elironrasib
DRUG: Zoldonrasib
DRUG: Ivonescimab
DRUG: Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)
DRUG: cetuximab (Cohort C2 Only)
DRUG: Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only)
DRUG: Daraxonrasib (Cohort B1 only)

Sponsor

Revolution Medicines, Inc.

Collaborators

[object Object]